Erin Lavelle

CIK: 0001737613

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

JBIO

Jade Biosciences, Inc.

Director

AVLN

Avalyn Pharma Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

JBIO
Jade Biosciences, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
34.8K shares-
AVLN
Avalyn Pharma Inc.
Apr 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27K shares-
JBIO
Jade Biosciences, Inc.
Apr 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
23K shares-

		Type	Shares	Price		Ownership
Jun 9, 2026	JBIO Jade Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	34,843	-	-	Direct
Apr 30, 2026	AVLN Avalyn Pharma Inc.	Award(A) Stock Option (Right to Buy)	26,978	-	-	Direct
Apr 29, 2025	JBIO Jade Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	23,017	-	-	Direct

1-3 of 3 transactions

About Lavelle Erin

Lavelle Erin (SEC CIK 0001737613) files insider reports with the SEC as Director of Jade Biosciences, Inc. (JBIO) and Director of Avalyn Pharma Inc. (AVLN).

Signal8 holds 5 ownership filings by Lavelle Erin (2 Form 3, 3 Form 4), filed between May 1, 2025 and Jun 11, 2026. Those filings report 3 transactions, from Apr 29, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lavelle Erin's filings is in WALTHAM, MA.

Recent filings by Lavelle Erin

Jun 9, 2026: Grant or award of JBIO derivative securities (Form 4, code A).
Apr 30, 2026: Grant or award of AVLN derivative securities (Form 4, code A).
Apr 29, 2025: Grant or award of JBIO derivative securities (Form 4, code A).

Other insiders filing for Jade Biosciences, Inc. (JBIO)

Eisner Mark, Director
CAIN CHRISTOPHER W., Director
DOBMEIER ERIC, Director
Klein Lawrence Otto, Director
Fairmount Funds Management LLC, Director
Dahms Bradford D., Chief Financial Officer

How to read Form 4 transaction codes